» Articles » PMID: 12239297

Study of Antigen-processing Steps Reveals Preferences Explaining Differential Biological Outcomes of Two HLA-A2-restricted Immunodominant Epitopes from Human Immunodeficiency Virus Type 1

Overview
Journal J Virol
Date 2002 Sep 20
PMID 12239297
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Cytotoxic T-lymphocyte (CTL) responses directed to different human immunodeficiency virus (HIV) epitopes vary in their protective efficacy. In particular, HIV-infected cells are much more sensitive to lysis by anti-Gag/p17(77-85)/HLA-A2 than to that by anti-polymerase/RT(476-484)/HLA-A2 CTL, because of a higher density of p17(77-85) complexes. This report describes multiple processing steps favoring the generation of p17(77-85) complexes: (i) the exact COOH-terminal cleavage of epitopes by cellular proteases occurred faster and more frequently for p17(77-85) than for RT(476-484), and (ii) the binding efficiency of the transporter associated with antigen processing was greater for p17(77-85) precursors than for the RT(476-484) epitope. Surprisingly, these peptides, which differed markedly in their antigenicity, displayed qualitatively and quantitatively similar immunogenicity, suggesting differences in the mechanisms governing these phenomena. Here, we discuss the mechanisms responsible for such differences.

Citing Articles

Definition of a New HLA B*52-Restricted Rev CTL Epitope Targeted by an HIV-1-Infected Controller.

El Kenz B, Schmidt K, Ogungbemi-Alt V, Bergmann S, Steininger P, Korn K Viruses. 2023; 15(2).

PMID: 36851781 PMC: 9959870. DOI: 10.3390/v15020567.


Identification and validation of expressed HLA-binding breast cancer neoepitopes for potential use in individualized cancer therapy.

Reimann H, Nguyen A, Sanborn J, Vaske C, Benz S, Niazi K J Immunother Cancer. 2021; 9(6).

PMID: 34172517 PMC: 8237736. DOI: 10.1136/jitc-2021-002605.


The presence of prolines in the flanking region of an immunodominant HIV-2 gag epitope influences the quality and quantity of the epitope generated.

Jallow S, Leligdowicz A, Kramer H, Onyango C, Cotten M, Wright C Eur J Immunol. 2015; 45(8):2232-42.

PMID: 26018465 PMC: 4832300. DOI: 10.1002/eji.201545451.


Antiviral activity of human immunodeficiency virus type 1 Gag-specific cytotoxic T lymphocyte targeting is not necessarily intrinsically superior to envelope targeting.

Chen D, Balamurugan A, Ng H, Yang O J Virol. 2010; 85(5):2474-8.

PMID: 21159882 PMC: 3067792. DOI: 10.1128/JVI.01726-10.


Multiplex RT-PCR amplification of HIV genes to create a completely autologous DC-based immunotherapy for the treatment of HIV infection.

Tcherepanova I, Harris J, Starr A, Cleveland J, Ketteringham H, Calderhead D PLoS One. 2008; 3(1):e1489.

PMID: 18231576 PMC: 2211536. DOI: 10.1371/journal.pone.0001489.


References
1.
Cassouto B, Novak L, Porgador A, Reiss Y . Production of a specific major histocompatibility complex class I-restricted epitope by ubiquitin-dependent degradation of modified ovalbumin in lymphocyte lysate. J Biol Chem. 1997; 272(34):21060-6. DOI: 10.1074/jbc.272.34.21060. View

2.
Yang O, Kalams S, Trocha A, Cao H, Luster A, Johnson R . Suppression of human immunodeficiency virus type 1 replication by CD8+ cells: evidence for HLA class I-restricted triggering of cytolytic and noncytolytic mechanisms. J Virol. 1997; 71(4):3120-8. PMC: 191444. DOI: 10.1128/JVI.71.4.3120-3128.1997. View

3.
Gallimore A, Dumrese T, Hengartner H, Zinkernagel R, Rammensee H . Protective immunity does not correlate with the hierarchy of virus-specific cytotoxic T cell responses to naturally processed peptides. J Exp Med. 1998; 187(10):1647-57. PMC: 2212291. DOI: 10.1084/jem.187.10.1647. View

4.
Pamer E, Cresswell P . Mechanisms of MHC class I--restricted antigen processing. Annu Rev Immunol. 1998; 16:323-58. DOI: 10.1146/annurev.immunol.16.1.323. View

5.
Beninga J, Rock K, GOLDBERG A . Interferon-gamma can stimulate post-proteasomal trimming of the N terminus of an antigenic peptide by inducing leucine aminopeptidase. J Biol Chem. 1998; 273(30):18734-42. DOI: 10.1074/jbc.273.30.18734. View